Verona Pharma plc, a clinical stage biopharmaceutical company, engages in the research, discovery, and development of therapeutic drugs for the treatment of acute and chronic respiratory diseases in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor that has completed Phase I and II clinical trials used for the treatment of chronic obstructive pulmonary disease and asthma, as well as in pre-clinical testing for the treatment of cystic fibrosis. It is also developing novel anti-inflammatory polysaccharides (NAIPs) that are in basic research phase to treat various respiratory and inflammatory diseases. The company is based in London, United Kingdom.
verona pharma plc
(VRP:London Stock Exchange)
3 More London Riverside
London, SE1 2RE
Phone: 44 20 3283 4200
|No competitor information is available for VRP.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.